Q-omics provides the consensus-scored AK8 profile across patient tissues and cancer cell-line models. AK8 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, AK8 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, AK8 RNA expression shows 17,023 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KICH, and TGCT as cancer lineages where AK8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AK8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AK8 survival associations across molecular data types. AK8 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AK8 RNA expression–survival associations across cancer types. High AK8 expression shows unfavorable associations in HNSC, but favorable associations in UVM, KIRP, KIRC, CESC and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for AK8 RNA expression.
This table summarizes AK8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for AK8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AK8 shows lower tumor expression in KICH, LUAD and THCA and higher tumor expression in COAD, LIHC and BRCA. The KICH box plot shows higher AK8 RNA expression in normal versus tumor tissue (log2 FC = −2.074, t-test p < 0.001).
This table shows molecular features associated with AK8 in patient tissues and cancer cell lines. In patient samples, AK8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, AK8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and KIDNEY.
